atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital – 12/20/22 – News

Tuesday, 20.12.2022 18:26 from GlobeNewswire

| Views: 63

Man with smartphone and tablet (icon image). © metamorworks / iStock / Getty Images Plus / Getty Images

NEW YORK (USA) and BERLIN (Germany), Dec. 20, 2022 (GLOBE NEWSWIRE) — atai Impact, the philanthropic arm of atai Life Sciences NV (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) on Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The one endowed with 2 million USD Fellowship Fund was announced in December 2021to enable research into the potential of psychedelics to address unmet patient needs in the mental health field and to support promising PhD students and other trainees in furthering their professional careers in this emerging field.

Over the course of the five-year program, grantees will have access to MGH’s innovative resources and expertise in neuroimaging technologies, cognitive neuroscience, cellular and molecular neurobiology, and clinical trial design, enabling them to discover, optimize, and implement novel experimental psychedelic neurotherapeutics can track.

The first cohort consists of PhD students whose research projects will primarily focus on mechanistic studies of psychedelics and related therapeutic interventions, including:

About Massachusetts General Hospital
Founded in 1811, Massachusetts General Hospital (MGH) is Harvard Medical School’s first and largest teaching hospital. The Mass General Research Institute operates the largest hospital-based research program in the country, with more than $1 billion in annual research and includes more than 9,500 researchers working in more than 30 institutes, centers and departments. In July 2022, MGH was ranked #8 on US News & World Report’s list of “America’s Best Hospitals.” The MGH is a founding member of the MGH Brigham Health System.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, express or implied, contained in this press release (specifically, with respect to the atai Impact program, the Fellowship Fund and other future atai philanthropic endeavors), statements that are not historical facts are forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including without limitation the important factors discussed under the heading “Risk Factors” in the atai’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) and in atai’s Quarterly Reports on Form 10-Q and subsequent filings with the SEC have been updated from time to time. atai disclaims any obligation to update or revise any forward-looking statements contained in this press release, except as required by applicable law

contact information

Investor contact:
By Stephen Bard
Chief Financial Officer

Press contact:
Allan Malievsky
Senior Director, External Affairs

Subscribe to more news about Atai Life Sciences shares free of charge


ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.